Merck (MRK), known as MSD outside of the United States and Canada, announced the first presentation of results from the Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate resulted in a statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol of 55.8% and of 59.7% in a post-hoc reanalysis compared to placebo at week 24. These late-breaking data will be presented for the first time today at the American Heart Association, AHA, Scientific Sessions 2025 and were selected for the Late-Breaking Science News Briefing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Insider Moves: JPMorgan, Adobe, Eli Lilly, McDonald’s, Merck
- Merck & Company: Hold Rating Maintained Amid Mixed Performance and Revised Guidance
- Merck’s (MRK) Fading Momentum Offers Quant Arbitrage Options Trade
- Merck enters R&D funding agreement with Blackstone Life Sciences
- Merck enters R&D funding agreement with Blackstone for sac-TMT